Inovio Pharmaceuticals
198 hedge funds and large institutions have $330M invested in Inovio Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 53 increasing their positions, 55 reducing their positions, and 31 closing their positions.
0.05% more ownership
Funds ownership: 3.4% → 3.46% (+0.05%)
4% less repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 55
5% less funds holding
Funds holding: 208 → 198 (-10)
19% less first-time investments, than exits
New positions opened: 25 | Existing positions closed: 31
23% less capital invested
Capital invested by funds: $428M → $330M (-$98M)
29% less call options, than puts
Call options by funds: $3.87M | Put options by funds: $5.47M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$37.4M |
| 2 |
Two Sigma Investments
New York
|
+$8.78M |
| 3 |
Morgan Stanley
New York
|
+$4.24M |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$3.07M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$3.03M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$24.6M |
| 2 |
SC
Sculptor Capital
New York
|
-$3.56M |
| 3 |
Goldman Sachs
New York
|
-$2.97M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$2.75M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$2.04M |
INO Hedge Fund Activity: Q1 2022 in Review
198 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Inovio Pharmaceuticals (INO) for Q1 2022, worth a combined $330M — down 23% from $428M a quarter earlier.
Sellers outnumbered buyers: 31 funds closed out of INO and 25 opened new positions — a net loss of 6 holders — while 55 trimmed existing stakes and 53 added.
The largest buyer was State Street, adding an estimated $37.4M. The largest seller was Wasatch Advisors, exiting entirely with an estimated $24.6M sold.
- 198 institutional investors held Inovio Pharmaceuticals (INO) as of Q1 2022, down from 208 in Q4 2021.
- Funds reported $330M of Inovio Pharmaceuticals stock for Q1 2022, down 23% quarter-over-quarter.
- 25 funds opened new Inovio Pharmaceuticals positions in Q1 2022 and 31 closed out, a net change of -6 holders.
- The largest Inovio Pharmaceuticals buyer in Q1 2022 was State Street, an estimated $37.4M added.
- The largest Inovio Pharmaceuticals seller in Q1 2022 was Wasatch Advisors, an estimated $24.6M sold.
Based on aggregated 13F filings for Q1 2022.